Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...
Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.
Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback